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ABSTRACT 
Cardiovascular disease is one of the leading causes of death worldwide. A major cause is 
atherosclerosis, which is a chronic inflammatory disease of medium and large size arteries 
characterized by the accumulation of cholesterol rich low-density lipoprotein (LDL) particles 
in the sub-endothelium layer of the vessel.   
Retention and modification of LDL triggers a systemic inflammatory response sustained by the 
humoral and cellular branches of the immune system. Early atherosclerosis initiation is often 
in the form of fatty streaks whilst necrotic core formation, inflammation, fibrosis and stenosis 
are characteristics of advanced atherosclerotic plaques. 
A protective humoral immune response is induced upon vaccination against oxidized LDL in 
experimental models of atherosclerosis, whilst studies on follicular B cells report an opposite 
pathogenic function of this subset. Furthermore, association studies on cardiovascular disease 
risk and antibody titers against oxidized LDL provide inconsistent results. Given these 
seemingly contradictory observations, the role of B cells and antibodies in atherosclerosis is 
still poorly understood. 
Atherosclerosis can develop as a silent disease over decades, and asymptomatic plaques usually 
have a robust fibrotic cap consisting of collagen and extracellular matrix deposited by smooth 
muscle cells. However, sudden clinical symptoms can occur in terms of myocardial infarction 
and stroke when the stability of the cap is impaired and the content of the plaque is released 
into the bloodstream.  
In this thesis we identify a potential mechanism involved in regulating the growth and the 
stability of atherosclerotic lesions. We first demonstrate that a germinal center response occurs 
promptly upon acute hypercholesterolemia, and is associated with an autoimmune-like 
deposition of immune complexes and systemic autoantibody production. Secondly, we 
characterize the effects of B cells in late stage atherosclerosis and we show that antibodies 
promote increased lesion size. Furthermore, we illustrate how these effects are depending on 
germinal center-derived antibodies. Thirdly, we observe that antibodies originating from the 
germinal center reaction induce a stable atherosclerotic plaque phenotype, in part through 
promoting smooth muscle cell proliferation. Finally, we report that antibodies regulate 
transcriptional pathways involved in maintaining the integrity, function and stability of the 
aorta. 
Collectively, the findings presented in this thesis identify germinal center B cells as an 
important factor affecting the composition, size and stability of the atherosclerotic plaque.   
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1 INTRODUCTION 
Atherosclerosis is thought to be an inflammatory disease that is triggered by accumulation and 
modification of lipoproteins within the intima layer of the artery. Atherosclerosis is a major cause 
for the development of acute cardiovascular events such as myocardial infarction and stroke and 
is the main cause of death worldwide. Rather than being simply the passive accumulation of 
cholesterol in the vessel wall, atherosclerosis is a complex chronic inflammatory disease which 
is thought to be triggered by the accumulation of apolipoproteinB containing lipoproteins in the 
sub-endothelial spaces of medium and large-sized arteries, with involvement of both innate and 
adaptive immunity in disease progression [1].  
The molecular series of events leading from infiltration of cholesterol-loaded lipoprotein particles 
to chronic inflammation and thrombosis are still not fully understood. In particular, the 
interrelationship of perturbed lipid metabolism with immune responses remains largely unknown. 
Wild-type mice do not develop spontaneous atherosclerosis as a result of their high circulating 
levels of ‘anti-atherosclerotic’ high-density lipoproteins (HDL) and low levels of ‘pro-
atherogenic’ low-density lipoproteins (LDL) and very low-density lipoproteins (VLDL). 
Consequently, mouse models for atherosclerosis need either genetic manipulation or diet 
intervention in order to achieve perturbations of the lipoprotein metabolism. The most commonly 
used mouse models are Apolipoprotein E–deficient mice (Apoe−/− mice), in which loss of the 
Apoe gene leads to hypercholesterolemia and spontaneous atherosclerosis, and LDL receptor–
deficient mice (Ldlr−/− mice) that develop atherosclerosis upon a lipid-rich diet.  
Combining these models with strains defective in immune system components has provided 
overwhelming evidence for both autoimmune and immune-protective mechanisms in 
atherosclerosis.  
 
1.1 Atherosclerosis 
Arteries are composed of three layers. The inner layer, facing the vessel lumen and in contact 
with the blood, is called the tunica intima and is composed of a monolayer of endothelial cells 
overlying a basal membrane. Next is the tunica media, the middle or media layer, which consists 
largely of smooth muscle cells. The outer lining is called tunica adventitia with connective tissue, 
fibroblasts, macrophages and other immune cell. Occasionally lymphoid structures called tertiary 
lymphoid organs (TLOs) are also seen in different arteries [2]. 
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Atherosclerotic lesion development is first visualized as fatty streaks, an early accumulation of 
lipid-containing cells in the sub-intimal space and, according to some observations, may 
physiologically regress during childhood [3].  
Atherosclerotic lesions are preferentially located in areas where the blood flow is disturbed or 
turbulent, such as in proximity to the branching sites of the arterial tree.  
Cholesterol-rich low density lipoprotein (C-LDL) is believed to play a major role in the 
establishment of atherosclerosis. Atherosclerosis initiation is driven by localized adhesion of 
ApoB-rich lipoproteins on sub-endothelial matrix proteoglycans. Retention of these particles is 
aided by lipoprotein lipase, sphingomyelinase, and phospholipase-A2. The modification, such as 
oxidation, of retained LDL triggers a cascade of immune reactions that eventually lead to an 
adaptive inflammatory response [4-7].  
 
1.1.1 Lipoproteins 
Lipoproteins are complex molecular entities consisting of a hydrophobic internal core made of 
lipids (cholesterol esters and triglycerides) and an outer shell made of apolipoproteins which 
allow transportation through the circulation between peripheral tissues and lipid deposits. The 
protein moiety also serves other functions such as providing structural support during the 
assembly of the lipoprotein, interacting with lipoprotein receptors and through exerting functional 
roles in enzymatic pathways.  
Lipoproteins are classified in categories depending on size, lipid content and density: increasing 
in density there are first chylomicron and chylomicron remnants (diameter > 80 nm with density 
< 0,9 g/ml), VLDL (30-80 nm), IDL (25-35 nm), LDL (18-25 nm), HDL (5-12 nm) and finally 
Lipoprotein(a) (~ 30 nm). Chylomicrons, VLDL and LDL are associated with a pro-atherogenic 
role, whilst HDL is considered to have protective effects, although this is debated.  
ApoB100 containing VLDL are formed in the liver as a result of metabolism of dietary lipids that 
are rich in triglycerides. In the muscle and adipose tissues, VLDL deposit triglycerides and are 
consequently enriched in cholesterol cargo. Because of this chemical change the lipoprotein 
species is now termed LDL.   
LDL, which also contains one ApoB100 molecule, interacts with the LDL receptor (LDLR) on 
several tissues, predominately the liver and intestine. Non-physiological conditions such as type 
2 diabetes, metabolic syndrome, hypertriglyceridemia and obesity, are associated with increased 
LDL concentration. LDL levels are the result of a balance between the rate of LDL production 
and clearance, both of which depend on the LDLR and also other receptors to a lesser extent.  
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HDL contains ApoA-1 and its function is the reverse transport of cholesterol. HDL uptakes 
cholesterol from peripheral storages via the ATP-binding cassette transporters (ABCA1, 
ABCG1) and transports it to the liver where it will be metabolized into bile acids [8]. 
 
1.1.2 The immune system in atherosclerosis 
Endothelial cells (ECs) can initiate inflammatory responses that rise in response to blood borne 
invaders, following engagement of their scavenger receptors and TLRs. ECs exposed to oxidized 
LDL (oxLDL) produce chemoattractant factors to recruit immune cells such as MCP-1, which 
binds the CCR2 receptor on monocytes, and produce M-CSF that triggers self-sustained 
macrophage differentiation. Moreover ECs control vascular tone via the inducible nitric oxide 
synthase 2 enzyme, interleukin-1 and endothelin, and the endothelium activation into an 
inflammatory phenotype marks the initial stages of early atherosclerosis [9, 10]. 
Macrophages are abundant in the atherosclerotic plaque. Activated macrophages show a pro-
inflammatory phenotype due to induction of the NF-kB cascade and upregulate their pattern 
recognition receptors such as surface scavenger receptors and toll like receptors (TLRs). Within 
the atherosclerotic plaque extensive macrophage proliferation amplifies the inflammatory 
environment, whereupon TNF-α, IFNγ, IL-6 and IL-1β, amongst other pro-inflammatory 
cytokines and growth factors, are secreted [11].  
Plaque degradation and remodeling occurs as a consequence of macrophage and smooth muscle 
cell derived proteases. Collagenases such as MMP-1, MMP-8, MMP-9, MMP-13 and cathepsins 
S, K, L and B are found in human and experimental lesions [11]. 
Nucleotide-binding domain, leucine-rich repeat-containing proteins (NLRP) represent sensors 
which function as pattern recognition receptors of the innate immune system (PRRs). The most 
studied member is NLRP3 due to its role in forming the inflammasome. The inflammasome is a 
multimeric protein complex which aggregates to its mature form in response to microbial 
molecules or “danger” signals. The assembly of the inflammasome initiates pro-caspase-1 self-
cleavage to generate active caspase-1, which in turn processes by proteolysis pro-interleukin1β 
to generate mature IL-1β. A variety of stimuli can activate the NLRP3 inflammasome: LPS, 
extracellular ATP, monosodium urate (MSU) crystals, cholesterol crystals and oxLDL. The role 
of NLRP3 in atherosclerosis is contradictory: a study using Nlrp3-/- bone marrow transplanted 
into Ldlr−/− and fed high-fat diet revealed a pathogenic role of NLRP3 whilst a double knock-out 
Apoe-/- Nlrp3-/- fed high fat diet showed no effect at all [12, 13]. 
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Circulating mast cells derive from a progenitor originating from the hematopoietic compartment. 
The cytoplasmic granules contain a variety of inflammatory mediators which have pro-
atherogenic effector functions. Present in the granules are vasoactive amines such as tryptases, 
and specific mast cell subclasses contain chymases. Human data and experimental models 
demonstrate a pro-atherogenic role of mast cells in atherosclerosis, despite their minor abundance 
in atherosclerotic plaque. The Ldlr-/- Kit (W-sh/W-sh) mouse lacks mast cells and shows reduced 
plaque burden together with reduced serum lipid levels and vascular inflammation [14]. Tryptases 
and chymases are reported to act both in chronic and acute manner on plaque progression and 
destabilization. Released granule contents drive leukocyte recruitment in situ and foam cell 
accumulation during plaque growth. At later stages they can activate MMPs to degrade 
extracellular matrix, induce SMCs apoptosis and promote vessel wall permeabilization and 
microhemorrhage, which are events linked with atherosclerotic plaque destabilization [15]. 
Natural Killer (NK) cells are scarce in plaques and localize in the shoulder regions. NK cells 
possibly promote atherosclerosis via IFNγ, GM-CSF and TNF-α production, and a lack of NK 
function in Ly49A transgenic bone marrow transplanted into Ldlr-/- recipients resulted in a 
protective phenotype [16]. 
Neutrophils are a minor cell population in established plaques. In their cytoplasmic granules are 
present large amount of reactive oxygen species (ROS) and matrix degrading proteases which are 
secreted extracellularly and possibly recruit monocytes, promote further LDL oxidation and 
enhance the pro-inflammatory milieu. Hypercholesterolemia triggers bone marrow-derived 
leukocytosis and neutrophilia which stimulate early atherosclerosis formation [17]. Aside from 
their proposed function in initiation of arterial inflammation, neutrophils might also play a role in 
destabilization of established plaques [18].  
 
The cross-talk between humoral, cellular immunity and lipid metabolism plays an important role 
in atherosclerosis and adaptive immune responses are detected during the phases of 
atherosclerotic plaque development and progression. The B-T cell interactions result in pro- or 
anti-inflammatory functions with production of antibody specificities against modified LDL. 
Rag1-/- and Scid-/- mice, two models lacking T and B cells, crossed into the atherosclerosis prone 
Apoe-/- and Ldlr-/- mice show a reduction in early atherosclerotic lesion formation, but upon 
western diet feeding Rag1-/- mice can still develop atherosclerosis [19, 20]. T lymphocytes in the 
plaque are mainly of the CD4+ T helper 1 memory/effector phenotype, compared with the CD8+ 
T cells within the plaque and in peripheral blood, at least in mice, and elicit a pro-atherogenic 
response. 
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Apoe-/- mice lacking CD4 cells display reduced atherosclerosis [21], although subsets of the CD4 
lineage are proposed to play different roles in atherosclerosis.  
Th1 cells are induced by the IL-12-IL-18 axis, that is established by activated pro-inflammatory 
macrophages. The required signature transcription factor for this lineage is TBET and the 
characteristic Th1 cytokine is the inflammatory IFN-γ. IFN-γ receptor-/- Apoe-/- mice show less 
atherosclerosis, and Th1 cells are associated with inflammation, increased disease burden and 
plaque instability with reduction in collagen fiber formation, increased expression of MHC II, 
enhanced protease and chemokine secretion, upregulation of adhesion molecules and pro-
inflammatory cytokines and activation of macrophages and endothelial cells [22, 23]. The Th2 
subset is reported to have opposite effects in atherosclerosis studies compared to Th1 cells. 
GATA3 transcription factor drives Th2 cell differentiation and IL-4, IL-5, IL-13 are signature 
Th2 cytokines. IL-5 possibly mediates protective functions by promoting B1 cell expansion and 
natural antibodies (NAbs) secretion [24]. IL-4 has complex effects on multiple cell types and was 
reported to promote atherosclerosis, whilst IL-13 might confer protection [25, 26]. Th17 cells are 
identified by the signature cytokine IL-17A and their role in atherosclerosis is controversial. In 
Apoe-/- mice IL-17A was associated both with protection and promotion [27, 28]. T regulatory 
cells are characterized by the production of IL-10 and TGF-β. This subset is strongly associated 
with dampening inflammation and reducing atherosclerotic lesion size, possibly by decreasing 
cholesterol levels [29-31].  
 
1.1.3 Atherogenesis 
Endothelial cells (ECs) in healthy arteries are normally resistant to adhesion of circulating 
leukocytes and molecules. Upon dyslipidemia, hypertension, hyperglycemia, smoking, and other 
pro-inflammatory stimuli, in the first phases of the response to retention of sub-intimal oxLDL 
the endothelium is activated. In this process the expression of adhesion molecules such as vascular 
cell adhesion molecule 1 (VCAM-1), intercellular cell adhesion molecule 1 (ICAM-1), and 
chemoattractants (i.e. MCP-1) which in turn mediate leucocyte attachment, is enhanced. The 
endothelial permeabilization and chemokine release allow monocytes to migrate into the sub-
endothelium, differentiate into macrophages in response to endothelial M-CSF, upregulate their 
pattern recognition receptors (PRRs) and phagocyte oxLDL to eventually become cholesterol-
laden foam cells [10].  
 
Next, immune cells such as activated IFN-γ releasing T cells, mast cells, monocytes 
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differentiating into inflammatory macrophages, antigen presenting cells (APCs), mast cells and 
NKT cells infiltrate from the shoulder region of the plaque and contribute to amplify and worsen 
the ongoing inflammatory response. The process is accelerated by continuous LDL accumulation 
in established lesions whilst a few smooth muscle cells (SMCs) migrate from the media to the 
sub-endothelial space and promote the formation of a fibrous cap of variable thickness composed 
of smooth muscle cells and secreted collagen. However, as the lesion progresses and becomes an 
atheroma, macrophages die and become necrotic areas (necrotic cores) consisting of cellular 
debris, cholesterol crystals, proteases, and thrombogenic material. Over decades these advanced 
plaques grow and give rise to clinical manifestations such as narrowing the lumen (stenosis) 
which impair the blood flow, or becoming susceptible to fibrous cap thinning, plaque rupture or 
erosion. If the cap stability is impaired this can ultimately lead to acute thrombotic vascular events 
such as myocardial infarction and stroke [7]. At this stage biomarkers such as C-reactive protein 
and IL-6 can be found in the circulation [32, 33]. 
 
Lesions that rupture typically have a thin, collagen-poor fibrotic cap with few SMCs and abundant 
macrophages, and often the rupture events occur in the shoulder area of vulnerable plaques [34]. 
Smooth muscle cells are the source of arterial collagen. The inflammatory cells may enhance 
plaque disruption by producing collagenolytic enzymes that can degrade collagen. The matrix 
metalloproteinase family (MMP) is the most studied and held responsible for the loss of collagen. 
The MMP member MMP-13 is associated with plaque collagen degradation in mouse models of 
atherosclerosis. Neutrophils produce proteases that further promote degradation of the 
extracellular matrix, thus weakening the fibrotic cap and destabilizing the plaque [35, 36]. When 
pro-coagulant necrotic material from the plaque core is exposed to the blood stream, it can react 
with the plasma coagulation components to form a thrombus. Main components of the thrombus 
are platelets, fibrin and erythrocytes. A thrombus can either interrupt blood flow locally or detach 
to become an embolus that can block the blood flow in distal arteries [37-40]. 
Occurrence of intra-plaque hemorrhage may also contribute to plaque instability.  
 
LDL is the most studied antigen in atherogenesis: LDL contains several epitopes recognized by 
B and T cells, and thereby induces both humoral and cellular immunity via a cross-talk between 
T and B cells. When an antigen presenting cell such as a dendritic cell first encounters the antigen, 
it processes and presents it on MHC II and then migrates through the lymphoid organs where 
interactions with T cells can take place. After a T cell bearing the specific TCR sequence for the 
epitope is recognized and activated, the CD4+ T helper cell migrates towards the B cell zone 
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where it will stimulate a cognate B cell. The activated B cell will rapidly secrete a first wave of 
IgM antibodies, then may move into the follicle to initiate a germinal center reaction. This can 
result in production of higher affinity antibodies against the antigen. Vaccination against modified 
LDL confers protective effects in experimental models of atherosclerosis and auto-antibodies 
against these modified LDL are found in the circulation of experimental models and humans [41-
44].  
Natural antibodies perform an innate-like immune response in atherosclerosis, in the form of 
germline encoded antibodies produced by B1 cells that recognize phosphocholine (PC) exposed 
on the surface of oxLDL, on the cell membrane of apoptotic cells and on Streptococcus 
pneumoniae surface, and eventually are thought to prevent atherosclerosis via different 
mechanisms. First, natural antibodies to a variety of oxidation-specific epitopes enhance 
clearance of apoptotic blebs released from dying cells. Secondly, they can inhibit scavenger-
receptor-mediated uptake of oxLDL by macrophages, thereby decreasing foam cell formation and 
macrophage derived inflammation which has pro-atherosclerotic effects. Finally, by forming 
immune complexes with various oxidized lipids, they may not only enhance clearance, but also 
provoke further immunogenic responses [1, 45-47]. 
 
1.2 B lymphocytes and antibodies in atherosclerosis 
In order to provide an efficient, full range protection against a very large number of different 
epitopes the B cell compartment needs to produce a broad and diverse spectrum of 
immunoglobulins (Igs). 
Few B lymphocytes are found in human and murine plaques, but immunoglobulins are present in 
the plaque [48-50].  Both immunoglobulins and B lymphocytes can also be found in the tertiary 
lymphoid organs in the artery adventitia of old Apoe-/- mice [51].  
 
The role of  antibodies and B cells in atherosclerosis has been investigated in a number of studies 
using mouse models. The data from these reports point towards a protective role of IgM 
antibodies against atherosclerosis. In fact, Ldlr-/- mice deficient also in serum IgM, Apoe-/- mice 
treated with polyclonal IgM or polyclonal IgG develop less atherosclerosis than the controls [52-
54]. Splenectomized Apoe-/- mice develop less atherosclerosis after receiving total splenic B cell 
extracts (B2 and B1), which contributed to the hypothesis that the spleen resident B cell pool 
confers protection against atherosclerosis [55].  
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µMT mice lacking the µ chain of the BCR have no B cells, and when their bone marrow is 
transplanted into Ldlr-/- mice this results in increased atherosclerosis [56]. On the contrary, 
ablation of follicular B2 cells but not B1 cells, via anti-CD20 therapy, reduces atherosclerosis 
which would indicate an opposite function [57]. Kyaw and colleagues also reported of an 
atherogenic role of B2 cells by using Tnfrsf13c-/- Apoe-/-  mice and an antibody depletion of 
BAFFR strategy [58, 59]. However, soluble BAFF might be atheroprotective per se beyond its 
effects on B cells, and accumulates in the BAFFR deficient models, as recently reported by 
Tsiantoulas et al. In this study the hypothesis was that soluble BAFF signalling dampens the rise 
of inflammatory atherogenic M1 polarized macrophages [60].  
As mentioned earlier natural IgM antibodies, mostly derived from B1 cells, have been reported 
to mediate atheroprotective roles, although the V heavy chain used in the prototypic T15 E06 
natural antibody is not responsible for the atheroprotective effects of this antibody [61] but the 
functional role of other immunoglobulin classes, in particular IgG, still remains unclear [62]. 
 
1.2.1 B cell development 
In the hematopoietic stem cell pool, Pax5 or B cell specific activator protein (BSAP), is a B cell 
lineage restricted transcription factor whose expression is detected starting from the pro-B cell 
stage until the mature B cell stage [63, 64]. 
Pax5 is one of the 9 members of the Pax5 family of transcriptional regulators, is considered a 
master regulator for commitment to the B cell fate [65] and its expression is down-regulated upon 
terminal differentiation to antibody secreting plasma cells [65, 66].  
 
BLIMP1 is the B-lymphocyte induced maturation protein. It is encoded by the Prdm1 gene and 
functions as the regulator of B and T cell terminal differentiation [67]. 
BLIMP1 acts as a transcriptional repressor by associating with deacetylases and histone-
modifying enzymes with repressor activities [68-70] and its targets are, between others, Pax5, 
Bcl6, Myc [65, 66, 71-73]. In particular, BLIMP1 repression of Pax5 is required for the 
differentiation of plasma cells [66].  
BLIMP1 is expressed in plasma cells produced upon T-I and (primary and secondary) T-D 
responses, and in long lived bone marrow plasma cells but not in memory B cells [74]. 
Bcl6 maintains repression of BLIMP1 in germinal center B cells to allow the GC reaction to 
continue [75]. 
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AID is the B cell–specific activation-induced cytidine deaminase (AID) enzyme, and is required 
for both class switching and somatic hypermutation of the immunoglobulin genes occurring in 
the germinal center. Upon AID over-expression there is an increase in IgA production over IgM, 
whilst AID deficiency is associated with aberrant class switch and hyper IgM syndrome [76]. 
In class switched and hypermutated B cells, AID is then repressed by the activation of BLIMP1 
which also inhibits the proliferative phenotype and drives the expression of X-box-binding 
protein 1 (Xbp-1), which in turn induces the immunoglobulin secreting pathway genes [77]. 
 
Genetic rearrangements of the immunoglobulin heavy (H) and light (L) chain loci known as 
V(D)J recombination are designed to assemble a functional BCR complex on the cell surface. At 
the common lymphoid progenitor (CLP) and pre-pro-B cell stage a DH gene is recombined with 
a JH gene segment by the RAG-1/RAG-2 recombination machinery. In the pro-B cell stage a VH 
segment is coupled to the pre-formed DHJH fragment to produce a rearranged VHDHJH heavy chain 
gene, which also contains the IgM constant region in form of a μ  polypeptide (Cμ). During the 
H chain recombination an enzyme called terminal deoxynucleotidyl transferase (TdT) includes N 
additions in the form of short nucleotide sequences at the VHDH  and DHJH  junctions. These 
recombined transcripts then associate with surrogate light chains and with the Igα/Igβ dimer on 
the cell surface to form the pre-BCR complex. In the following pre-B cell stage the L chain is 
rearranged into a VLJL segment similarly to the H chain by RAG-1/RAG-2, however no N 
additions are included. At the end of the pre-B stage, the newly produced L transcript is paired 
with the previously recombined μ H chain to form a surface bond IgM immunoglobulin. This 
IgM associates with the Igα/Igβ dimer to assemble a BCR complex. The maturation then 
continues with repertoire selection of the BCR pool. The final aim is to increase the affinity and 
specificity of the existing BCRs in order to neutralize the sample of autoreactive BCRs from the 
immature B cell compartment by employing one of the following mechanisms: editing, anergy or 
deletion. During this negative selection, cross-linked BCRs reactive against self are inactivated 
or removed. BCR editing is performed by the RAG-1/RAG-2 enzyme complex which introduces 
further genetic rearrangements into the L chains. Anergy is induced when the BCR is modestly 
engaged and in the absence of T-cell help, which turns the B cell into a non-responsive state in 
which there is no downstream signalling following the BCR cross-linking. Deletion is achieved 
via apoptosis, which is induced in two ways, via either the intrinsic or extrinsic pathway. 
 
The surviving B cells eventually break away from the bone marrow stromal cells and move into 
the circulation to reach the spleen to complete the maturation. This stage is called transitional 1 
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(T1), characterized by expression of CD24 (HSA) and CD95. At first the T1 cell is still expressing 
surface bound IgM whilst the latter transitional 2 (T2) stage expresses increasing levels of IgD 
and decreasing IgM. The surviving T2 cells constitute the mature, circulating, naive B cell pool 
which migrates to the periphery into the secondary lymphoid organs. The viability of the 
transitional B cell pool is strongly dependent upon the survival factor BAFF/BAFF-Receptor 
signalling [10, 11].  
 
1.2.2 B cell subsets 
The origin of the B1 and B2 lineages is unclear. There are two hyphothesis for their development. 
According to the “dual lineage model”, early on in the HSC compartment there is a differentiation 
into a B1-precursor and a B2-precursor. However in the alternative theory, the “activation 
model”, a common B1/B2 precursor matures into the transitional stage: the BCR signalling will 
trigger either the B1 or B2 development.  
 
1.2.2.1 B1 cells 
Depending on the presence of the CD5 molecule on the cell surface, B1 cells can be further 
classified into B1a and B1b cells. It is unclear whether B1a and B1b cells develop from a common 
progenitor or they differentiated early on from two different hematopoietic precursors. B1 cells 
are derived from the fetal liver and the adult bone marrow, and the adult B1 cell compartment is 
able to maintain a homeostatic expansion called self-replenishment. After birth they migrate to 
populate the spleen and the serosal cavities of the body such as peritoneum and pleura. Upon 
activation they migrate into the spleen to produce most of the circulating natural antibodies, 
mainly of the IgM isotype. Natural antibody production by B1 cells begins already at one week 
of age and occurs in an innate, fast, T-independent manner. It confers humoral protection against 
bacterial pathogens. Consequently, natural antibodies show germline VDJ recombination, poly-
reactivity and low affinity.  
 
1.2.2.2 B2 cells 
B2 cells are the conventional mature B cells found in the peripheral secondary lymphoid organs 
and constitute most of the B cells in spleen, lymphnodes, blood and the recirculating population 
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in bone marrow. During adult life, B2 cells are continuously replenished from bone marrow 
precursors. Within the B2 cell pool there are two subsets: the follicular B (FoB) and the marginal 
zone B (MZB) cells.  
 
Follicular B cells are found in the lymphoid follicles in spleen and lymph nodes. Their life span 
is months, are resting at steady conditions and react usually within days after exposure to a T-
dependent antigen. FoB can produce class switched, high affinity and highly specific antibodies 
in T-dependent responses. In fact, FoB that have undergone class-switch recombination (CSR) 
and somatic hypermutation (SHM) processes are responsible for secreting most of the circulating 
IgA, IgG and IgE antibodies.  
 
The marginal zone B cell pool colonize the splenic marginal zone from the marginal sinus and 
patrol the interface between red and white pulp, therefore constituting a first line of defense 
against blood-borne TI (T-independent) antigens. They can, however, shift towards the follicle 
zone for epitope presentation to the T cells in the T zone. MZ B cells react to lipid antigens by 
presenting them on CD1d, have a low threshold for activation and mount a fast, innate-like, 
antibody response consisting mainly of IgM and IgG3 antibodies.  
 
B cells migration from the bone marrow to the periphery is driven by chemokine and cytokine 
expression. Classic B cell chemokines are CXCR4, which binds to CXCL12, and CXCR5, which 
recognizes CXCL13. Naive B cells are attracted to the splenic red pulp, where CXCL12 is 
strongly induced, and are driven to the white pulp follicles via CXCL13 recruitment. Other 
immunologically active sites express different receptors for other B cell chemokines [78, 79].  
 
1.2.2.3 Germinal centers 
The goal of the germinal center reaction is to produce a significant amount of highly specific 
antibodies against the invading pathogen during the course of an infection or against neo-self, 
sterile epitopes, such as during atherosclerosis [17, 80]. 
The germinal center is the result of the clonal expansion of B cells consequent to a T-dependent 
immune response in a secondary lymphoid organ. The pathogen is first captured in the external 
area of the follicle called the T cell zone by a B cell or another antigen presenting cell (APC): 
then the microbe is engulfed, processed and presented in MHC II to a responding CD4+ naive T 
cell. If the peptide presented in MHC is recognized by the TCR this provides the so called signal 
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1, which must be also accompanied by a second co-stimulatory interaction, such as the CD40-
CD40 ligand interaction, between many others.  
According to this “two-signal” model of T cell activation, upon both positive signals the primed 
T cell migrates towards the B-T cell border to interact with the naive cognate B cell. If a TCR 
reacts with the MHC-epitope complex on the B cell, the T cell differentiates into a T follicular 
helper cell (Tfh). A Tfh population is usually noticeable from day 2 of the GC reaction and is 
identified by the expression of the surface markers CXCR5, PD1 and GL7 and production of IL-
21 [17, 81]. 
The genetic rearrangements that can take place in the GC are the class switch recombination 
(CSR) and the somatic hypermutation (SHM). The GC is supplemented by the cytokine and 
chemokine milieu, which will trigger positive selection of the B cells whose V chains have gained 
the highest affinity after affinity maturation.  
The initial expansion that occurs within the early GC is not of a mono-clonal kind, in fact more 
than a single clone is found, that originate from non related B progenitors [64, 70, 76]. 
Within the developing GC two structurally different zones can be identified: the dark and the light 
zone. GC B cells migrate rapidly between the two zones in an iterative manner many times during 
the GC activity. The dark zone of the GC is composed by rapidly dividing CXCR4hi CD83lo 
CD86lo centroblasts undergoing SHM of their immunoglobulin genes. When they express the 
rearranged BCR with the highest affinity they shuttle towards the light zone of the GC as 
CXCR4lo CD83hi CD86hi centrocytes, where antigen-driven selection takes place upon 
interaction with the follicular dendritic cell pool [17, 68]. Both GC B cells and Tfh cells can 
migrate not only between the different zones of the GC but also between different GCs.  
Two responses rise from the germinal center: a plasma cell and a memory reaction, and both will 
migrate into the blood as the GC reaction extinguishes [69]. 
The post-GC plasma cells are the immediate result of the GC reaction. They secrete a high amount 
of recombined and mutated immunoglobulins, mainly IgG but IgA and IgE as well.  
The post-GC memory cells are long lived (years), resting B cells that survive latent in bone 
marrow niches. This compartment can be readily activated upon a second encounter with the 
same pathogen and will begin a specific, high affinity humoral defense.  
 
Memory B cells are not only produced by GCs, in fact they can be generated either by T-
independent or T-dependent B-cell responses [101]. Memory B cells deriving from T-
independent or extra-follicular T-dependent activation are generally short lived, although this 
notion has been challenged [102,103]. On the other hand, memory B cells derived from T-
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dependent reactions (either from GCs or extra-follicular clusters) can live for months in mice and 
for years or decades in humans. 
 
1.2.3 Effector functions of B cells and antibodies 
As antibody producing cells, B lymphocytes are key elements of the immune system in 
physiologic defense mechanisms against invading antigens and non physiologic deleterious 
responses towards self and modified self components via autoantibody production. But their 
function is not limited to antibody related effects, in fact B cells can also participate in 
autoimmune diseases through cytokine production, which can be beneficial or deleterious [82].  
B cell derived IL-10 and IL-35 promoted recovery in EAE models [32, 83] and production of IL-
21 by B cells can drive B regulatory cells differentiation which reversed established EAE [33]. 
IL-6 producing B cells  worsen disease progression of EAE models and at least partly drive 
disease in MS patients [84]. Lymphotoxin, granulocyte macrophage colony stimulating factor 
(GM-CSF) and tumor necrosis factor TNF-α are also reportedly increased in MS patients [85, 
86]. 
B cell production of IFN-γ promotes autoimmune experimental arthritis possibly via 
differentiation and accumulation of Tfh cells [62]. Class-switched activated memory B cells 
found in synovial fluid of RA patients express RANKL, a cytokine driving osteoclast 
differentiation and function, which can exacerbate bone loss in the inflamed joint [87]. 
B1a derived IRA B cells produce GM-CSF in sepsis models and aggravate atherosclerosis in 
irradiated Ldlr-/- mice following reconstitution with Csf2-/- bone marrow [88, 89]. 
 
Immunoglobulins exhert their protective functions in order to inhibit a pathogen infection or its 
spreading via different mechanisms such as  opsonization, complement activation, phagocytosis, 
antibody-dependent cellular cytotoxicity (ADCC). It is possible that several of these mechanisms 
occur in parallel or sequentially. Opsonization is the process by which antibodies recognize and 
coat the surface of the pathogen. An opsonized microorganism or infected cell is the classic 
example of clearance via phagocytosis, being the target of Fc receptor-bearing phagocytes. 
Neutralization can occur in different ways. In one, immunoglobulins neutralize the pathogen by 
inhibiting the attachment to the host tissues via a process called agglutination, mostly known as 
dependent on the polymeric IgM and IgA antibodies, by which the pathogen is trapped in the 
mucous surfaces. Another neutralization strategy is targeting immunoglobulins against the 
adhesins on pili or fimbriae of the microbe which are normally used to phisically attach to the 
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host cells. Neutralization can also take place at later stages during the infection, intracellularly, 
when antibodies interfere with the pathogen`s replication steps in the infected cell.  
Furthermore immunoglobulins, both natural antibodies and IgG, can bind and activate the 
complement, through which the infected cell or pathogen is cleared by phagocytes or removed 
via cell lysis.  
The biological function of antibodies is the response generated by the interaction of the Fc 
fragment with an Fc receptor expressed on the surface of the target cell. The nature of such 
response depends on a number of variables which are, among others, the identity of the target 
cell, of the immunoglobulin (or immune-complex), and the cytokine environment. 
Antibody-dependent cytotoxicity occurs when an antibody bound to either a pathogen or an 
infected cell also engages an interaction with an Fc receptor on the effector cell, which eventually 
leads to lysis or apoptosis of the target [90]. 
As a final note on the activity of antibodies, a recent study in the context of atherosclerosis 
illustrates the generation of an Ldlr-/- E06-scFv-/- murine model deficient for the effector function 
of the stereotypical E06 natural antibody. E06-scFv-/- is a single chain variable fragment of E06 
lacking the Fc fragment, therefore the E06-scFv antibody can not mediate Fc-dependent functions 
and is only able to bind oxidized phospholipids. This clearance of oxidized phospholipids 
prevents macrophage uptake and activation, which results in reduced inflammation and 
atherosclerosis [91]. 
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1.3 Smooth muscle cells 
In healthy arteries smooth muscle cells compose the media layer of the vessel wall and control 
the tone and diameter of the vessel by using their repertoire of contractile proteins. At a steady 
state SMCs proliferate slowly with low extracellular matrix secreting activity. However, it has 
been proposed that in the atherosclerotic vessel the smooth muscle cells may migrate from the 
arterial media to the sub-intimal space. Here SMCs undergo phenotypic changes that promote 
their proliferation and deposition of extracellular matrix, collagen and elastic fibers, which 
eventually form the fibrotic cap that contains the atherosclerotic plaque. Some reports have 
introduced the term “SMC transdifferentiation” to describe this process [92, 93]. Detailed analysis 
of the origin of intra-plaque and fibrous cap SMCs revealed how, in early atherosclerosis, few 
medial SMCs might migrate across the shoulder region and clonally proliferate into the lesion. 
The expansion of few selected clones could give rise to a variety of phenotypes, with lipid-loaded 
SMCs found in the body of the plaque and a layered structure in the SMCs forming the fibrous 
cap [94]. 
 
There is no unique lineage transcription factor for the identification of mature differentiated 
SMCs but rather a series of them, which are also expressed by other cell types, at certain 
developmental stages or in not healthy conditions. Such markers are smooth muscle actin alpha 
(α-SMA) [95], SM22 [96], smooth muscle myosin heavy chain (SMHC) [97] , h1-calponin [96] 
and smoothelin [78]. 
Moreover, a number of reports have shown that SMCs can start expressing myeloid markers such 
as CD68 [79] whilst other studies reported the presence of α-SMA positive cells of myeloid origin 
extracted from the atherosclerotic plaque [98] and hematopoietic stem cells can originate vascular 
SMCs in vivo and in vitro [99]. 
In conclusion, it is still not possible to unequivocally identify and track SMCs by using a lineage 
marker or the classical α-SMA marker, and this is therefore the major limitation in understanding 
the phenotype switch and migration activity of SMCs in atherosclerosis. 
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2 AIMS 
The aim of my PhD is to discover the functions of B cell subsets and antibodies in 
atherosclerosis, in particular by elucidating: 
 
I.  The function of V1 heavy chain encoded innate-like natural antibodies in atherosclerosis 
(paper I). 
II. The adaptive immune response to acute hypercholesterolemia in an inducible model of 
atherosclerosis (paper II). 
III. The role of germinal center derived immunoglobulins in atherosclerotic plaque size and 
stability (paper III). 
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3 METHODOLOGICAL CONSIDERATIONS 
3.1 Mouse models 
The mouse models presented in this thesis were crossed into the Apoe-/-background in order to 
develop spontaneously atherosclerosis or on the Ldlr-/- strain, which is susceptible to lesion 
formation upon western diet. In order to deplete plasma cell formation we used the Blimp1Flox 
CD19Cre Apoe-/- model, where plasma cell depletion is conditionally achieved in a B cell 
restricted way. The Pax5Flox CD23Cre Apoe-/- model has a follicular and marginal zone B cell 
defect. To achieve a germinal center B cell specific depletion we crossed the Pax5Flox AicdaCre 
Apoe-/- mouse. Furthermore, we created a novel inducible atherosclerotic Apoe-/- mouse, the 
Rosacre26ERT2 ApoeFlox which is a model of acute inducible hypercholesterolemia and 
atherosclerosis. Finally, we assessed the role of the VHS107.1.42 heavy chain gene in 
atherosclerosis development in both the VhS107.1.42-/-Apoe-/- and VhS107.1.42-/- Ldlr-/-. 
 
3.2 Experimental methodology 
A single dose of 9 mg tamoxifen was administered by oral gavage and, in order to monitor 
in time the rise in hypercholesterolemia, the mice were routinely bled several days after 
tamoxifen administration.  
For the atherosclerotic plaque stability studies we performed a plaque rupture model [100]. 
10 to 12 week-old mice were maintained on a normal chow diet during the course of the 
study. We performed incomplete ligation of the right common carotid artery below the 
bifurcation. In the following four weeks after surgery the arterial intima remodeling processes 
formed a neointima and a carotid atherosclerotic plaque. To induce plaque rupture we placed 
a cuff around the common carotid artery, next to the ligation, to induce collagen degradation. 
The mice were sacrificed 4 days after cuff placement and both right, injured, and control left 
carotid arteries were analyzed. A ruptured plaque was identified by the presence of a 
thrombus in the carotid lumen which is microscopically confirmed with a positive fibrin 
staining.  
For the carotid artery ligation model, similarly to the plaque stability model, we performed 
right carotid artery complete ligation at the bifurcation on 10 to 12 week-old mice on chow 
diet, and 28 days later we sacrificed the animals and the carotid arteries were processed for 
thrombus evaluation.  
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Bone marrow was harvested from tibia and femur of donor mice. Each recipient mouse 
received Gy irradiation. Following irradiation they received the donor bone marrow by tail 
vein injection. Recipient mice were then maintained in a pathogen-free facility for 
approximately a 3 months recovery time.   
Aortic smooth muscle cells from 6 to 8 week old Apoe-/- mice were isolated from the aorta 
after removal of the adventitia. The media was dissociated to a single cell suspension via 
enzymatic digestion with collagenase and elastase, then SMCs were cultured and expanded. 
For experiments, fetal calf serum was replaced in the culture media with 2% serum either 
from control or experimental mice. Cell proliferation was calculated as average 
confluence/area using live cell imaging.  
Splenectomy was performed on 10 weeks old mice. The animals were anaesthetized and the 
spleen was extracted from a 1cm incision made on the left side of the abdomen. After, the 
vessels and nerves were slowly cauterized, the peritoneum and skin were sutured. For sham 
operation the mice were surgically cut as the splenectomized but re-sutured thereafter.  
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4 RESULTS AND DISCUSSION 
4.1 VHS107.1.42 does not protect against atherosclerosis  
Germline encoded natural IgM antibodies are implicated in the recognition and clearance of 
oxLDL, processes associated with protection against atherosclerosis. At the same time natural 
antibodies also confer protection against Streptococcus pneumoniae infection. The archetypal 
natural antibody T15 or E06 recognises phosphatidylcholine in the bacterial cell wall or in the 
POVPC headgroup exposed on oxidized LDL or in the apoptotic blebs found on the 
membranes of dying cells [101]. T15/E06 is encoded by the VHS107.1.42 immunoglobulin 
heavy chain gene which has not been directly linked to protection against atherosclerosis, 
therefore in paper I we crossed VHS107.1.42-deficient mice with the atherosclerosis-prone 
Apoe-/- and Ldlr-/- strains. These mice lost early immune responses against phosphocholine after 
immunization, confirming the specificity of VHS107.1.42 towards PC, but the T15 titers as well 
as other antibodies reacting to oxidized LDL were unaffected. Assessment of atherosclerosis 
development showed no protection. In summary, we concluded that natural IgM antibodies 
using the VHS107.1.42 chain are not likely involved in conferring protection against 
atherosclerosis, despite driving the humoral response to PC and protecting against S. 
pneumoniae infection [102] (Figure 1). 
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Figure 1 
A. Plasma anti-PC IgM antibody titers in the response to PC-KLH immunization in 
VHS107.1.42
-/- Apoe-/- mice. 
B. T15 IgM antibody measured in plasma of VHS107.1.42
-/- Apoe-/- mice. 
C. Development of atherosclerosis in the aortic root of Apoe-/- mice deficient for the 
VHS107.1.42 antibody. 
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4.2 Autoimmune-like response to acute hypercholesterolemia 
Hypercholesterolemia is associated with vascular inflammation and hence susceptibility to 
atherosclerosis. However, the causality between hyperlipidemia, inflammation and early 
atherosclerosis is not yet clear.  
Therefore, in paper II we hypothesized that a rapid conversion to an Apolipoprotein E 
deficient state would reveal whether the immune system also responds during the transition to 
hypercholesterolemia. 
We created a tamoxifen inducible Apoe-/- mouse, in which loss of APOE induced in the adult 
mouse resulted in rapid and maintained hypercholesterolemia and subsequent 
spontaneous atherosclerosis. This transition to hypercholesterolemia induced local adaptive 
immune responses in the spleen. We detected two waves of germinal centers formation, first at 
the transition to hypercholesterolemia which occurred with Th1 and Tregs activation and 
preceded the appearance of atherosclerosis. At this early time point there was also a systemic 
autoimmune reaction to hypercholesterolemia, with immune complexes deposition and plasma 
autoantibodies production. The second wave of germinal centers was detected in aged mice in 
which atherosclerosis was established and resembled the chronic late stage inflammatory 
disease. Therefore, we concluded that germinal centers are an indicator of early atherosclerotic 
plaque formation and acute hypercholesterolemia induces an autoimmune response (Figure 2). 
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Figure 2 
A. Germinal centers development upon transition to hypercholesterolemia (tamoxifen 
induction) in the spleen of inducible Apoe mice. 
B. Immune complexes deposition in the kidney after transition to hypercholesterolemia in 
inducible Apoe mice. 
C. Atherosclerosis development in the aortic root of inducible Apoe recipient mice transplanted 
with bone marrow from germinal center deficient mice. 
 
4.3 Germinal centers drive large and stable atherosclerotic plaque 
We then asked, how does the loss of immunoglobulins impact upon atherosclerosis burden, 
without affecting T dependent and independent immune responses nor the function and 
viability of B cells (such as antigen presentation and cytokine production)?  
To do so, in paper III we specifically ablated antibody producing plasma cells. Deletion of the 
Prdm1 gene results in B cells that are functionally normal but are largely unable to secrete 
immunoglobulins. Next, we crossed this mouse with a Cre transgenic line. Cd19Cre/+ deletes in 
all mature B cells and hence prevents antibody production. This mouse was crossed into the 
Apoe-/- background to develop spontaneous atherosclerosis. Therefore, we created a 
hypercholesterolemic atherosclerotic mouse model unable to mount humoral responses. 
Interestingly, mice lacking immunoglobulins develop less atherosclerosis than their littermate 
controls. We could visualize a qualitative difference in the phenotype of the lesions between 
control and experimental mice, with the latter being richer in lipid-loaded foam cells and with 
a lower content of smooth muscle actin positive cells, compared with control plaques. Reduced 
smooth muscle actin and lipid enriched plaques are associated with an unstable plaque 
phenotype, therefore we assessed the stability of atherosclerotic lesions by using a carotid 
ligation with cuff placement model [100] to mechanically induce the rupture of the plaque. Our 
experimental mouse showed a higher rupture rate compared with controls. 
We hypothesized that SMCs are affected by the absence of antibodies: we observed that, in 
vitro, Apoe-/- primary aortic vascular SMCs cultured in medium containing plasma from our 
control mouse proliferate more than those growing in medium containing experimental mouse 
plasma. Hence, we hypothesized that plasma antibodies act in a FcγR-dependent manner which 
ultimately can mediate the NF-kB pro-inflammatory pathway [103]. Next, we wanted to 
investigate what immunoglobulin species is responsible for the smooth muscle cell phenotype 
we observed. We assessed the growth of Apoe-/- aortic vascular SMCs in the presence or 
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absence of plasma containing IgG-derived germinal center derived antibodies. We observed 
that the cells grew significantly faster in presence of IgG antibodies. We were also able to 
translate this observation in vivo, by reconstituting our experimental mouse with purified IgG 
to the same level as that observed in controls. We observed that IgG reconstitution was able to 
`rescue` lesion size and that neointima formed upon carotid ligation was also similar to the 
control group. We then investigated the origin of the IgG antibodies in vivo and we used a novel 
mouse model to assess the role of germinal center-derived IgG antibodies in atherosclerosis. 
We developed a mouse strain that conditionally ablate the transcription factor Pax5 using a 
stage specific Cre line in B cells. Pax5 performs an essential function in maintaining B cell 
identity, and is currently the only known B cell specific factor that is constantly required for 
correct B cell function throughout all developmental stages [48].  
In this model we deleted Pax5 using AicdaCre. AICDA is specific to the germinal center B cells 
and loss of Pax5 within this structure results in the loss of germinal centers. Consequently, in 
this model, somatic hypermutation, memory B cell formation and affinity maturation are lost.  
We therefore crossed the Apoe-/- mouse with the Pax5f/f AicdaCre mouse. Examination of 
atherosclerosis development revealed that loss of the systemic GC formation and GC derived 
antibodies decreased atherosclerosis burden. Furthermore, loss of germinal center antibodies 
in the plasma from this mouse can not promote in vitro vascular SMCs proliferation suggesting 
that these antibodies might be responsible for the unstable plaque phenotype. To test this 
hypothesis we inhibited the germinal center reaction via anti-ICOS ligand therapy in an 
inducible Apoe model and evaluated plaque stability: the loss of germinal center antibodies 
resulted in unstable atherosclerotic plaques. To understand the effect of antibodies on SMCs 
we analyzed the transcriptome of the aortic media in our antibody deficient model by mRNA 
sequencing. Intriguingly, upon loss of antibodies, genes involved in the coagulation, iron 
metabolism, lipid metabolism and inflammatory pathways were upregulated. Genes involved 
in viability and function of SMCs were downregulated in the antibody deficient mouse, 
possibly linking transcriptome to the unstable atherosclerotic plaque phenotype. In summary, 
in paper III we demonstrated that germinal center derived IgG antibodies affect the composition 
of the atherosclerotic plaque, increase lesion size and promote plaque stabilization via 
maintaining smooth muscle cells transcriptome which results in a more stable aorta (Figure 3).  
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Figure 3 
A. Atherosclerosis development in the aortic root of antibody deficient mice. 
B. Immunofluorescence staining for fibrin to detect thrombus formation in the lumen on carotid 
artery after carotid ligation and cuff protocol, on antibody deficient mice. Quantification of 
rupture events is shown in the right panel. 
C. Atherosclerosis development in the aortic root of germinal center deficient mice. 
D. Immunofluorescence staining for fibrin to detect thrombus formation in the lumen on carotid 
artery after carotid ligation and cuff protocol, on germinal center deficient mice. Quantification 
of rupture events is shown in the right panel. 
E. Volcano plot of RNA sequencing data from aorta of antibody deficient mice.  
 
4.4 Concluding remarks 
Immunization experiments against oxLDL conferred protection from atherosclerosis due to a 
humoral response which was directed towards oxidation epitopes on the surface of modified 
circulating lipoproteins. The germline, unswitched IgM with low specificity and broad 
spectrum of affinities originate from B1 B cells, which are considered the protective branch of 
the B cell lineage. In fact, splenectomy experiments resulted in atheroprotection which was 
accredited to the loss of protective antibodies. The stereotypical natural antibody is the T15 
E06 clone, which is constructed from the VHS107.1.42 heavy chain gene. This chain was 
therefore indirectly linked to atheroprotection. We demonstrated, in paper I, that such gene is 
not able to confer protection against atherosclerosis, and probably the T15-id+ positive IgM 
can be made from alternative immunoglobulin heavy chains, which are however unable to 
protect against Streptococcus infection or provide primary anti-PC responses.  
Chronic hypercholesterolemia in atherosclerosis triggers vascular inflammation and 
contributes to disease progression, but little is known about the effects of acute hyperlipidemia. 
Therefore, we created an inducible hypercholesterolemic Apoe model which we described in 
paper II. Interestingly, we observed that the transition to acute hypercholesterolemia 
associated with an induced Apoe null state triggers splenic activation in terms of GC, Tregs and 
Tfh expansion and an autoimmune response with systemic autoantibody production and 
immune-complexes deposition in the kidneys. This autoimmune reaction to acute 
hypercholesterolemia was dependent on germinal center B cells.  
Germinal centers rise from the follicular B2 milieu upon sterile and non-sterile stimuli, such as 
autoimmune inflammation and pathogen infections, respectively. B2 cells contain the mature 
follicular and marginal zone B milieu, which includes the germinal centers. In atherosclerosis, 
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opposite to the role of B1 cells, the more abundant B2 cell pool has a more unclear effect in 
experimental atherosclerosis, with a possible pathogenic action. The role of germinal center B 
cells in atherosclerosis has never been directly assessed. For the first time to our knowledge, 
we demonstrated in paper III that germinal center derived antibodies affect lesion content, 
promote increased atherosclerosis lesion size, but these plaques have a `stable` phenotype.  
 
Such observation raises the debate lesion size versus plaque stability in cardiovascular disease. 
Of note, the carotid ligation with cuff model is an artificial setup. It mimics an acute event, and 
it is a model for neointima formation and acute athero-thrombosis rather than literally 
atherosclerotic plaque rupture. From a translational point of view, the vulnerable murine 
atherosclerotic plaque resembles human late stage lesions for the presence of fibrotic cap, 
necrotic core and intraplaque hemorrhage. But one limiting factor is that spontaneous rupture 
events in murine models are hardly ever detected [104]. On a similar note, there is still margin 
for improvement also of evaluation and quantification strategies of atherosclerosis burden.  
 
It could be of interest to establish if the immune effects we described are directly acting on the 
plaque itself and to determine the clonal specificity of such germinal center antibodies involved 
in the stabilization or growth of the lesion. Moreover, a regression study focused on germinal 
center derived antibodies could shed light on the effects of the adaptive antibodies in 
atherosclerosis presented in my thesis. 
As a final note, in summary this thesis provides the rationale for the germinal center humoral 
response in promoting initiation of atherosclerosis and progression of lesion size via 
maintaining transcriptional integrity of the aortic wall (Figure 4). 
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Figure 4  
Atherosclerosis formation begins already at 10 weeks of age with the appearance of fatty 
streaks in the Apoe-/- mouse on conventional diet. By the age of 20 weeks, the lesions have 
grown in size, contain an inflamed necrotic core and a fibrotic cap produced by smooth muscle 
cells that migrated from the media to the sub-intimal space. Antibodies derived from germinal 
centers affect the composition and phenotype of atherosclerotic plaques. In particular, these 
antibodies affect the smooth muscle cell population in the atherosclerotic wall by promoting 
specific transcriptional pathways. Therefore, in the absence of germinal center-derived 
antibodies the lesions are smaller in size and possibly contain less smooth muscle cells. 
Consequently, the lesions have a thinner fibrotic cap which makes them be more susceptible to 
rupture events.  
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